Odyssey Therapeutics, Inc.’s (NASDAQ:ODTX) Lock-Up Period Set To End on November 4th

Odyssey Therapeutics’ (NASDAQ:ODTX) lock-up period will expire on Wednesday, November 4th. Odyssey Therapeutics had issued 15,500,000 shares in its initial public offering on May 8th. The total size of the offering was $279,000,000 based on an initial share price of $18.00. After the expiration of the company’s lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ODTX. Weiss Ratings started coverage on shares of Odyssey Therapeutics in a research note on Tuesday, August 11th. They issued a “sell (d+)” rating for the company. JPMorgan Chase & Co. lifted their target price on shares of Odyssey Therapeutics from $26.00 to $29.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Raymond James Financial began coverage on shares of Odyssey Therapeutics in a research note on Thursday, October 8th. They issued an “outperform” rating and a $42.00 target price on the stock. HC Wainwright started coverage on shares of Odyssey Therapeutics in a research note on Thursday, August 27th. They issued a “buy” rating and a $44.00 target price on the stock. Finally, UBS Group started coverage on shares of Odyssey Therapeutics in a research report on Monday, October 12th. They issued a “buy” rating and a $27.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $35.33.

Odyssey Therapeutics Price Performance

Odyssey Therapeutics stock opened at $19.54 on Friday. The company has a market cap of $939.09 million and a P/E ratio of -2.89. Odyssey Therapeutics has a one year low of $15.10 and a one year high of $29.05. The stock’s 50 day moving average is $21.79.

Odyssey Therapeutics (NASDAQ:ODTX) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.74) earnings per share for the quarter. On average, sell-side analysts anticipate that Odyssey Therapeutics will post -6.08 EPS for the current year.

Institutional Investors Weigh In On Odyssey Therapeutics

Several large investors have recently made changes to their positions in ODTX. Citadel Advisors LLC acquired a new stake in shares of Odyssey Therapeutics during the 2nd quarter worth about $4,162,000. State Street Corp bought a new position in Odyssey Therapeutics during the 2nd quarter valued at about $1,477,000. Finally, The Manufacturers Life Insurance Company acquired a new position in Odyssey Therapeutics in the second quarter valued at about $601,000.

Odyssey Therapeutics Company Profile

Odyssey Therapeutics is a clinical-stage biotechnology company focused on discovering and developing precision medicines for immune-mediated diseases and cancer. The company combines computational biology, functional genomics, and experimental drug discovery to identify therapies directed at disease-driving biological pathways.

Its research programs are centered primarily on small-molecule medicines and other targeted approaches intended to modulate the immune system or address vulnerabilities in cancer cells.